堃博医疗-B早盘一度涨超18%,月内股价实现翻倍。截至发稿,股价上涨13.29%,报1.79港元,成交额1407.32万港元,港股市值9.41亿港元。堃博医疗宣布,公司核心产品,自主研发的全球首款经自然腔道射频消融肺癌治疗器械--BroncAblate智衡一次性使用肺部射频消融导管正式获得中国国家药品监督管理局(NMPA)批准在中国上市,引领肺癌治疗进入超微创介入治疗时代。国元国际本月初曾发布研报...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.